Nant cancer vaccine
US11071774B2 · kind B2 · utility
1Cited by
7References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 6, 2020 |
| Grant date | Jul 27, 2021 |
| Priority date | — |
| Expiry date | Feb 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.